BREA, Calif, June 24, 2019 /PRNewswire-PRWeb/ -- NuLiv Science USA, a leading developer of nutraceutical ingredients for the dietary supplement industry, reported new findings of its fifth human clinical study on the sport nutraceutical, ActiGin®, published in the Journal of Functional Foods.
Participants ingested ActiGin® (standardized to 5 mg Rg1) or Placebo (PLA) one hour before exercise in a double-blind, placebo-controlled crossover design. Muscle biopsies were collected before, immediately after, and three hours post-exercise from participants to examine the dynamical changes of satellite cell numbers, Myf5 expression, and muscle remodeling of skeletal muscle in response to an acute bout of endurance cycling exercise at 70% of maximal oxygen uptake (V02max).
Satellite cell availability determines the resilience of muscles against physical challenges (like intense exercise), which is evidenced by delays in post-injury remodeling and resolution of muscle inflammation in Pax7+ satellite cell-depleted muscle.
The study results indicate ActiGin® supplementation increases Myf5 and mRNA and restored satellite cell numbers after exercise as well as total glutathione and centrally nucleated myofibers three hours post-exercise. The authors also noted that supplementing with ActiGin® prevents Pax7+ satellite cell depletion of exercising skeletal muscle and restores myogenesis following intense exercise.
"ActiGin® continues to demonstrate a high standard in our industry as it relates to supporting energy, stamina, and recovery. With a fifth human clinical study now complete, ActiGin® is ramping up as the go-to ingredient for stamina and recovery products," noted NuLiv Science president, Richard Wang.
To learn more about ActiGin®, please visit http://www.nulivscience.com
Please direct media inquiries to:
SOURCE NuLiv Science